

## CLAIMS

We claim:

1. A crystalline rupatadine form-B characterized by having the melting point of about 110 - 115°C.
2. The crystalline rupatadine form-B as defined in claim 1, further characterized by a differential scanning calorimetric thermogram with endothermic peak at about 112°C.
3. The crystalline rupatadine form-B as defined in claim 1, further characterized by an x-ray powder diffraction spectrum having peaks expressed as 2 $\theta$  at about 18.2, 18.5, 18.8, 19.5, 20.2, 22.7 and 23.8 degrees.
4. The crystalline rupatadine form-B as defined in claim 1, further characterized by an x-ray powder diffraction spectrum having peaks expressed as 2 $\theta$  at about 9.4, 9.8, 14.9, 16.4, 18.2, 18.5, 18.8, 19.5, 20.2, 22.7, 23.8, 24.5 and 28.4 degrees.
5. The crystalline rupatadine form-B as defined in claim 1, further characterized by a Fourier transform Infrared (FTIR) spectrum as shown in figure 3.
6. A process for preparation of crystalline rupatadine form-B as defined in claim 1, which comprises suspending rupatadine in n-hexane, n-heptane, cyclohexane, diethyl ether or diisopropyl ether, stirring for at least about one hour and isolating rupatadine free base as crystalline form-B.
7. The process according to claim 6, wherein the stirring of the suspension is carried out for 1 to 10 hours at below the boiling temperature of the solvent used.
8. The process according to claim 7, wherein the stirring of the suspension is carried out for 3 - 6 hours at 15°C to the boiling temperature of the solvent used.
9. The process according to claim 8, wherein the stirring of the suspension is carried out for 3 - 6 hours at ambient temperature.
10. The process according to claim 6, wherein the isolation of the crystalline form-B is carried out by filtration or centrifugation.
11. A pharmaceutical composition comprising crystalline rupatadine form-B as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.